Home » Stocks » BLRX

BioLineRx Ltd. (BLRX)

Stock Price: $2.69 USD -0.05 (-1.82%)
Updated Jun 21, 2021 11:21 AM EDT - Market open
Market Cap 129.75M
Revenue (ttm) n/a
Net Income (ttm) -33.57M
Shares Out 46.06M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $2.69
Previous Close $2.74
Change ($) -0.05
Change (%) -1.82%
Day's Open 2.77
Day's Range 2.67 - 2.77
Day's Volume 275,901
52-Week Range 1.40 - 6.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.

Other stocks mentioned: ASLN, FLXN, ICMB, MRNS
2 weeks ago - Zacks Investment Research

TEL AVIV, Israel, May 26, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for th...

3 weeks ago - PRNewsWire

TEL AVIV, Israel, May 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudi...

1 month ago - PRNewsWire

Cocrystal Pharma, Inc. (NASDAQ: COCP), ChemoCentryx, Inc. (NASDAQ: CCXI), Neuronetics, Inc. (NASDAQ: STIM) and BioLineRx Ltd. (NASDAQ: BLRX) are among the biggest health care movers Tuesday.

Other stocks mentioned: CCXI, COCP
1 month ago - Benzinga

BioLineRx (NASDAQ: BLRX) has announced positive top-line results from GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, combined with granulocyte colony-stimulating factor (G-...

1 month ago - Benzinga

TEL AVIV, Israel, May 4, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive top-line results f...

1 month ago - PRNewsWire

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other stocks mentioned: APTX, CYCN, LCTX, PTN
1 month ago - PennyStocks

TEL AVIV, Israel, April 15, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company has pre...

2 months ago - PRNewsWire

TEL AVIV, Israel, Feb. 23, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for t...

3 months ago - PRNewsWire

BioLineRx Ltd. is a late-stage biopharmaceutical company focused on oncology with 2 multi-indication candidates (Phase 3 and Phase 1/2a) and 1 approved product. BioLineRx's pipeline and products consist...

4 months ago - Seeking Alpha

TEL AVIV, Israel, Jan. 22, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its previo...

4 months ago - PRNewsWire

TEL AVIV, Israel, Jan. 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to demand, the u...

5 months ago - PRNewsWire

TEL AVIV, Israel, Jan. 19, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into ...

5 months ago - PRNewsWire

Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Combination w...

Other stocks mentioned: ESPR, HTBX
6 months ago - Benzinga

TEL AVIV, Israel, Dec. 16, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from the triple c...

6 months ago - PRNewsWire

BioLineRx's (BLRX) CEO Phil Serlin on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

TEL AVIV, Israel, Nov. 23, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for t...

6 months ago - PRNewsWire

BLRX stock is blasting off on Friday morning after the company reported strong results from a Phase-3 trial for one of its cancer treatments. The post BioLineRX News: Why BLRX Stock Is Skyrocketing Toda...

7 months ago - InvestorPlace

Shares of BioLine RX Ltd. soared 47% on heavy volume of 14.1 million shares in premarket trading Friday, after the Israel-based biopharmaceutical company announced positive interim results from a Phase ...

7 months ago - Market Watch

TEL AVIV, Israel, Oct. 30, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planne...

7 months ago - PRNewsWire

TEL AVIV, Israel, Oct. 29, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's lead drug c...

7 months ago - PRNewsWire

TEL AVIV, Israel, Aug. 19, 2020 /PRNewswire/ -- BioLineRx Ltd.

10 months ago - PRNewsWire

BioLine RX Ltd (BLRX) CEO Philip Serlin on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

- On track to report three significant data readouts in next few months - - Completes successful financings, raising gross proceeds of $13.4 million; sufficient to reach multiple important milestones- -...

10 months ago - PRNewsWire

TEL AVIV, Israel, July 31, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaud...

10 months ago - PRNewsWire

BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.

10 months ago - Zacks Investment Research

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Other stocks mentioned: AVGR, PTI, VCNX, VIVE
11 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 29th

Other stocks mentioned: AXU, GSV, NTNX
1 year ago - Zacks Investment Research

TEL AVIV, Israel, May 27, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitled 'BL-8040...

1 year ago - PRNewsWire

TEL AVIV, Israel, May 26, 2020 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into d...

1 year ago - PRNewsWire

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

TEL AVIV, Israel, May 20, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for th...

1 year ago - PRNewsWire

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.

1 year ago - Zacks Investment Research

How To Play BioLineRx In 2020

1 year ago - Seeking Alpha

The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.

1 year ago - Zacks Investment Research

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.

1 year ago - Zacks Investment Research

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

BioLineRx (BLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 years ago - Zacks Investment Research

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About BLRX

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy fi... [Read more...]

Industry
Biotechnology
IPO Date
Jul 25, 2011
CEO
Philip Serlin
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
BLRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for BioLineRx stock is "Buy." The 12-month stock price forecast is 13.00, which is an increase of 383.27% from the latest price.

Price Target
$13.00
(383.27% upside)
Analyst Consensus: Buy